Prospects for personalised treatment of patients with radioiodine-avid locally recurrent or metastatic thyroid cancer
Affiliation
Bristol Cancer Institute, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol,Issue Date
2021
Metadata
Show full item recordAbstract
Although most patients with metastatic or inoperable locally recurrent differentiated thyroid cancer have radioiodine-avid disease, the outcome for patients who do not achieve remission with radioiodine therapy is poor. Most centres use fixed empirical activities of radioiodine to treat these patients, which is in contrast to other areas of oncology, where there is a shift to more individualised treatment. The use of dosimetry techniques to calculate a more appropriate activity of radioiodine for each patient may increase the effectiveness of radioiodine therapy but is more complex, time-consuming and of unproven benefit. This review addresses some of the limitations of empirical radioiodine therapy, discusses existing dosimetry-based approaches to individualising therapy and proposes further work in this area. A prospective randomised controlled trial comparing empirical activities of radioiodine with activities guided by a combination of lesional dosimetry and maximum safe dose has not been carried out previously. Although considerable challenges in the design of such a study remain, a network of centres in the UK now has the potential to take this forward.Citation
Beasley M, Garcez K. Prospects for Personalised Treatment of Patients with Radioiodine-avid Locally Recurrent or Metastatic Thyroid Cancer. Clin Oncol (R Coll Radiol). 2021;33(2):75-9.Journal
Clinical OncologyDOI
10.1016/j.clon.2020.11.010PubMed ID
33339681Additional Links
https://dx.doi.org/10.1016/j.clon.2020.11.010Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2020.11.010
Scopus Count
Collections
Related articles
- Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer.
- Authors: Abuqbeitah M, Demir M, Kabasakal L, Çavdar İ, Uslu-Beşli L, Yeyin N, Razavikhosroshahi S, Sönmezoğlu K
- Issue date: 2018 Nov
- Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
- Authors: Jarzab B, Handkiewicz-Junak D, Wloch J
- Issue date: 2005 Dec
- Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
- Authors: Teunissen JJ, Kwekkeboom DJ, Kooij PP, Bakker WH, Krenning EP
- Issue date: 2005 Jan
- [Combined radioiodine (I131) treatment and radio-guided surgery for recurrent cervical well-differentiated thyroid cancer].
- Authors: Schachter P, Shimonov M, Lorberboim M
- Issue date: 2005 Mar
- Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies.
- Authors: Pryma DA, Mandel SJ
- Issue date: 2014 Sep